Skip to main content
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Introduction
Featured Profiles
Genmab
Geron
SpringWorks
Special Series
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Conference Correspondent
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Small Cell Lung Cancer
Evolving Landscapes in Multiple Myeloma
OFS Summit
Multimedia
All Videos
Case-Based Exchanges
Voices From ASCO 2025
Best Practices in Breast Cancer Therapy | OFS
Interview with the Innovators
Rapid Reactions
Webinars
Quick Quiz
Subscribe
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Introduction
Featured Profiles
Genmab
Geron
SpringWorks
Special Series
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Conference Correspondent
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Small Cell Lung Cancer
Evolving Landscapes in Multiple Myeloma
OFS Summit
Multimedia
All Videos
Case-Based Exchanges
Voices From ASCO 2025
Best Practices in Breast Cancer Therapy | OFS
Interview with the Innovators
Rapid Reactions
Webinars
Quick Quiz
Subscribe
Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy
Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy
By
Jonathan Wesley Riess, MD, MS
Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy
Lung cancer is the second-most common type of cancer in the United States, including approximately 235,000 new cases each year, 84% of which are non–small-cell lung cancer (NSCLC).
Read More ›